Bronchitis Research Today is a free monthly online journal that collates and summarizes the latest research about Bronchitis, including details on pulmonary disorders, symptoms, diagnosis, treatment, prevention.

Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

Dosanjh A

University of California-San Diego, School of Medicine, La Jolla, CA, USA. adosanjh@ucsd.edu

Pirfenidone has a simple chemical structure, but may have profound implications for transplantation management. One of the leading causes of allograft failure is chronic allograft dysfunction, manifested by chronic inflammation and chronic fibrosis [Estenne, M., Hertz, M.I., 2002. Bronchiolitis obliterans after human lung transplantation. AJRCCM. 166, 440-444.]. This review summarizes the literature to date on Pirfenidone in the setting of transplantation, and those studies pertinent to the mechanisms of organ rejection and possible use of Pirfenidone in transplantation patients.

Published 24 April 2006 in Eur J Pharmacol, 536(3): 219-22.
Full-text of this article is available online (may require subscription).

© 2005-2008 Bronchitis Research Today. All Rights Reserved.